Difference between revisions of "Volasertib (BI-6727)"
Jump to navigation
Jump to search
(Created page with "=Mechanism of action= Polo-like kinase 1 ([http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=9077 PLK1]) inhibitor =Preliminary data= # Döhner H, Lübbert M, Fiedl...") |
m |
||
| Line 3: | Line 3: | ||
=Preliminary data= | =Preliminary data= | ||
| + | ==[[Acute myeloid leukemia]]== | ||
# Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann OG, Müller-Tidow C, Krämer A, Raffoux E, Döhner K, Schlenk RF, Voss F, Taube T, Fritsch H, Maertens J. Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy. Blood. 2014 Jul 8. [Epub ahead of print] [http://bloodjournal.hematologylibrary.org/content/early/2014/07/07/blood-2014-03-560557.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/25006120 PubMed] | # Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann OG, Müller-Tidow C, Krämer A, Raffoux E, Döhner K, Schlenk RF, Voss F, Taube T, Fritsch H, Maertens J. Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy. Blood. 2014 Jul 8. [Epub ahead of print] [http://bloodjournal.hematologylibrary.org/content/early/2014/07/07/blood-2014-03-560557.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/25006120 PubMed] | ||
Revision as of 04:20, 21 November 2014
Mechanism of action
Polo-like kinase 1 (PLK1) inhibitor
Preliminary data
Acute myeloid leukemia
- Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann OG, Müller-Tidow C, Krämer A, Raffoux E, Döhner K, Schlenk RF, Voss F, Taube T, Fritsch H, Maertens J. Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy. Blood. 2014 Jul 8. [Epub ahead of print] link to original article PubMed
History of changes in FDA indication
- 4/14/2014: Granted FDA orphan drug status for treatment of acute myeloid leukemia.